Navidea biopharmaceuticals announces publication of study examining tc99m tilmanocept imaging of arterial inflammation in people with hiv

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “increased macrophage specific arterial inflammation relates uniquely to non-calcified plaque and specific immune activation pathways in people with hiv: a targeted molecular imaging approach,” based on work performed at the massa
NAVB Ratings Summary
NAVB Quant Ranking